

# CITATION REPORT

List of articles citing

**Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis**

**DOI: 10.1016/j.tmaid.2020.101791**

**Travel Medicine and Infectious Disease, 2020, 36, 101791.**

**Source:** <https://exaly.com/paper-pdf/77145580/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
197	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. <b>2020</b> , 7, ofaa446		34
196	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 546	4.9	5
195	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. <b>2020</b> , 4, e288-e299		15
194	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 37, 101873	8.4	38
193	Olfactory and gustative disorders for the diagnosis of COVID-19. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 37, 101875	8.4	9
192	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <b>2020</b> , 262, 118541		4
191	CD147 as a novel receptor in the pathogenesis of SARS-CoV-2: Is there any correlation with the risk of COVID-19 in dermatological diseases?. <b>2020</b> , 33, e14443		2
190	Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. <b>2020</b> , 56, 106144		76
189	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. <b>2020</b> , 38, 100776		20
188	In response to: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. <b>2020</b> , 93, 631		1
187	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. <b>2020</b> , 29, 100645		34
186	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. <b>2020</b> , 56, 106212		9
185	Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020. <b>2020</b> , 56, 106219		28
184	Risch Responds to "How to Consider Low Reported Death Rates in COVID-19". <b>2020</b> , 189, 1230-1231		2
183	THE AUTHOR REPLIES. <b>2020</b> , 189, 1444-1449		3
182	A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 99, 138-139	10.5	
181	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. <b>2020</b> , 56, 106129		7

180 Azithromycin/hydroxychloroquine. **2020**, 1824, 65-65

179 Current Options in the Treatment of COVID-19: A Review. **2020**, 13, 1999-2010

5

178 Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19. **2020**, 133, 104682

16

177 Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?. **2020**, 12, 1139-1144

1

176 Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. *Travel Medicine and Infectious Disease*, **2020**, 38, 101906

8.4 15

175 Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. **2020**, 28, 625-634

12

174 Observational study of azithromycin in hospitalized patients with COVID-19. **2020**, 15, e0238681

14

173 Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. **2020**, 82, 38-47

64

172 Immune responses during COVID-19 infection. **2020**, 9, 1807836

49

171 Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. **2020**, 18, 17

13

170 The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. **2020**, 25,

4

169 Deciphering SARS-CoV-2 Virologic and Immunologic Features. *International Journal of Molecular Sciences*, **2020**, 21,

6.3 12

168 Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. *Journal of Clinical Medicine*, **2020**, 9,

5.1 8

167 Mortality & Hydroxychloroquine; Politics & Pandemic: Strange liaisons lead to strange correlations: Mortality & Hydroxychloroquine; Politiques & Pandémie: D'étranges liaisons impliquent d'étranges corrélations. **2020**, 38, 100749

0

166 In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. **2020**, 25,

42

165 Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. **2020**, 9, 435-449

35

164 Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. **2020**, 38, 100709

48

163 Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. *International Journal of Infectious Diseases*, **2021**, 102, 110-114

10.5 3

162	Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial. <b>2021</b> , 53, 141-170		15
161	How useful is serology for COVID-19?. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 102, 170-171	10.5	6
160	Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. <b>2021</b> , 134, 16-22		55
159	Hydroxychloroquine Failure: The End Does Not Justify the Means. <b>2021</b> , 72, e439		1
158	Reply to Million et al. <b>2021</b> , 72, e440-e441		
157	Different pattern of the second outbreak of COVID-19 in Marseille, France. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 102, 17-19	10.5	8
156	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 138-140	9.5	8
155	Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. <b>2021</b> , 57, 106242		2
154	Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients. <b>2021</b> , 57, 106236		1
153	Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19. <b>2021</b> , 57, 106238		
152	Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. <b>2021</b> , 57, 106241		1
151	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <b>2021</b> , 133, 111008		14
150	Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. <b>2021</b> , 57, 106239		10
149	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. <b>2021</b> , 57, 106243		14
148	Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 132-133	9.5	0
147	Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 39, 101954	8.4	1
146	Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective. <b>2021</b> , 44, 95-105		7
145	The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium. <b>2021</b> , 2, 100019		18

144	Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19. <b>2021</b> , 538, 132-136		21
143	Rational for meta-analysis and randomized treatment: the COVID-19 example. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 6-8	9.5	4
142	Asymptomatic hypoxia in COVID-19 is associated with poor outcome. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 102, 233-238	10.5	41
141	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 19-27	9.5	144
140	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. <b>2021</b> , 40, 1649-1657		1
139	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. <b>2021</b> , 12, 6		7
138	Therapeutic options for COVID-19: a quick review. <b>2021</b> , 33, 67-84		4
137	Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IB $\beta$ -Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry.		2
136	Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing. <b>2021</b> , 13, 7		8
135	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. <b>2021</b> , 180, 356-368		7
134	Counter Intuitive COVID-19 Propagation Dynamics in Brazil. <b>2021</b> , 427-435		
133	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. <b>2021</b> , 28,		11
132	Therapeutic and Vaccine Strategies for Stopping the COVID-19 Pandemic Based on Structural and Molecular Modeling Studies of Virus-Ganglioside Interactions. <b>2021</b> , 273		
131	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <b>2021</b> , 93, 2694-2704		9
130	Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis. <i>F1000Research</i> , <b>2021</b> , 10, 40	3.6	34
129	An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. <b>2021</b> , 10, 1945		2
128	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. <b>2021</b> , 54, 37-45		2
127	Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?. <b>2021</b> , 54, 997-1000		6

126	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. <b>2021</b> , 27, 281-290		8
125	Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 40, 101980	8.4	21
124	Chloroquine and COVID-19: role as a bitter taste receptor agonist?. <b>2021</b> , 40, 100843		
123	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. <b>2021</b> , 75, e14182		2
122	Chronotherapy in COVID-19 Disease. <b>2021</b> , 36, 2466-2467		
121	Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. <b>2021</b> , 14, 365-370		6
120	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. <b>2021</b> , 33, 100773		28
119	Safety Consequences of Off-Label Drugs Used for COVID-19. <b>2021</b> , 44, 399-402		0
118	COVID-19 re-infection. <b>2021</b> , 51, e13537		22
117	Hydroxychloroquine in Hospitalized Patients with Covid-19. <b>2021</b> , 384, 881-882		4
116	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. <b>2021</b> , 29, 343-366		6
115	Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. <b>2021</b> , 9,		7
114	Comparisons between the Neighboring States of Amazonas and Par��n Brazil in the Second Wave of COVID-19 Outbreak and a Possible Role of Early Ambulatory Treatment. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	4
113	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <b>2021</b> , 30, 694-706		13
112	Factors associated with the spatial heterogeneity of the first wave of COVID-19 in France: a nationwide geo-epidemiological study. <b>2021</b> , 6, e222-e231		30
111	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. <b>2021</b> , 12, 576093		10
110	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. <b>2021</b> , 41, 1189-1202		5
109	Comment to Sands et al. - No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 105, 216	10.5	

108	A Perspective on COVID-19 Management. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
107	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. <b>2021</b> ,		
106	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. <b>2021</b> , 9, E693-E702		7
105	The time to offer treatments for COVID-19. <b>2021</b> , 30, 505-518		9
104	The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. <b>2021</b> , 39, 159-170		4
103	Low Dose Chest CT and Lung Ultrasound For the Diagnosis and Management of COVID-19. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
102	Hydroxychloroquine as prophylaxis when treating patients with coronavirus disease 2019 □ Perception of frontline health care workers in South India. 73, 141-146		
101	Coronavirus disease 2019 pandemic in Greece, February 26 - May 3, 2020: The first wave. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 41, 102051	8.4	5
100	In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. <b>2021</b> , 14, 1155-1165		4
99	Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy. <b>2021</b> , 16, e0251746		5
98	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 8,		
97	Non-Intrusive Assessment of COVID-19 Lockdown Follow-Up and Impact Using Credit Card Information: Case Study in Chile. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	
96	SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
95	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis.		0
94	Post-COVID Syndrome: An Insight on Its Pathogenesis. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	43
93	Emergence and outcomes of the SARS-CoV-2 'Marseille-4' variant. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 106, 228-236	10.5	23
92	Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region. <i>African Journal of Primary Health Care and Family Medicine</i> , <b>2021</b> , 13, e1-e8	1.9	0
91	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <i>Pathogens and Global Health</i> , <b>2021</b> , 115, 456-466 <sup>3.1</sup>		5

90	COVID-19 and drugs: pathophysiology and therapeutic approaches. <i>Comptes Rendus - Biologies</i> , <b>2021</b> , 344, 27-42	1.4	2
89	Evaluation of Strategies to Fight COVID-19: The French Paradigm. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
88	COVID-19 Management at IHU Méditerranée Infection: A One-Year Experience. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
87	Science's Response to CoVID-19. <i>ChemMedChem</i> , <b>2021</b> , 16, 2288-2314	3.7	2
86	Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 931-932	9.5	29
85	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
84	Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. <i>International Immunopharmacology</i> , <b>2021</b> , 96, 107636	5.8	6
83	Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , <b>2021</b> , e2276	11.7	2
82	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 3297-3315	12.7	7
81	High-flow oxygen therapy in elderly patients infected with SARS-CoV2 with a contraindication for transfer to an intensive care unit: A preliminary report. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 108, 1-3	10.5	5
80	Mécanismes possiblement impliqués dans les effets antiviraux de la chloroquine et de l'hydroxychloroquine : Quelle réalité pour le traitement de la COVID-19 ?. <i>Toxicologie Analytique Et Clinique</i> , <b>2021</b> , 33, 237-237	0.4	
79	Making trials part of good clinical care: lessons from the RECOVERY trial. <i>Future Healthcare Journal</i> , <b>2021</b> , 8, e243-e250	0.9	6
78	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through IB of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. <i>Covid</i> , <b>2021</b> , 1, 263-275		0
77	Antibiotics Prescribing in Intensive Care Settings during the COVID-19 Era: A Systematic Review. <i>Antibiotics</i> , <b>2021</b> , 10,	4.9	5
76	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. <i>European Journal of Pharmacology</i> , <b>2021</b> , 905, 174191	5.3	8
75	Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives. <i>International Journal of Nanomedicine</i> , <b>2021</b> , 16, 5713-5743	7.3	8
74	Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations. <i>Chemical Physics Letters</i> , <b>2021</b> , 777, 138745	2.5	2
73	Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1887-1895	4.4	2

72	Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 5597-5606	2.3	2
71	Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. <i>Tuberculosis and Respiratory Diseases</i> , <b>2021</b> , 84, 299-316	3.2	5
70	Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. <i>Infection, Genetics and Evolution</i> , <b>2021</b> , 95, 105092	4.5	7
69	Therapeutic Management of COVID-19 Patients. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , <b>2022</b> , 210-220	0.2	1
68	Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection. <i>Asian Journal of Chemistry</i> , <b>2021</b> , 33, 1718-1722	0.4	1
67	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1501-1506	3.7	18
66	Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion. <i>Immunology Letters</i> , <b>2020</b> , 228, 83-85	4.1	3
65	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1159-1184	5.1	41
64	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. <i>American Journal of Therapeutics</i> , <b>2020</b> , 27, e573-e583	1	3
63	Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19.		5
62	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.		2
61	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.		2
60	In Vitro Safety "Clinical Trial" of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy. <b>2020</b> ,		3
59	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. <i>Pan African Medical Journal</i> , <b>2020</b> , 37, 9	1.2	8
58	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , <b>2020</b> , 13, 4673-4695	4.2	20
57	Diarrhoea in Patients with COVID-19. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , <b>2020</b> , 30, 51-56	1	5
56	COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. <i>Zoological Research</i> , <b>2020</b> , 41, 517-526	3.4	26
55	Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond. <i>Nutrients</i> , <b>2020</b> , 13,	6.7	22

54	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <i>Annals of the Academy of Medicine, Singapore</i> , <b>2020</b> , 49,	2.8	7
53	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. <i>Rambam Maimonides Medical Journal</i> , <b>2020</b> , 11,	1.8	6
52	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <i>Advances in Rheumatology</i> , <b>2021</b> , 61, 60	3	4
51	Current knowledge about the etiopathogenesis and therapy options for COVID-19. <i>Zdravstvena Zastita</i> , <b>2020</b> , 49, 43-54	0.1	1
50	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for Covid-19 Outpatients in Saudi Arabia.		
49	Clinical use of antiviral, antibiotic and immunomodulatory drugs in hospitalized COVID-19 patients: a retrospective study in Bandung, Indonesia. <i>F1000Research</i> , 10, 1091	3.6	0
48	Considerations for scuba and breath-hold divers during the COVID-19 pandemic: A call for awareness. <i>Diving and Hyperbaric Medicine</i> , <b>2020</b> , 50, 413-416	1	0
47	Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa.		
46	COVID-19.		2
45	Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 44, 102191	8.4	4
44	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <i>Annals of the Academy of Medicine, Singapore</i> , <b>2020</b> ,	2.8	1
43	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> ,	2.9	1
42	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. <i>Therapeutics and Clinical Risk Management</i> , <b>2021</b> , 17, 1187-1198	2.9	0
41	Long-term persistence of symptoms of dyspnoea in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , <b>2021</b> ,	10.5	0
40	Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study. <i>BMC Medicine</i> , <b>2021</b> , 19, 279	11.4	2
39	F-FDG-PET Imaging for Post-COVID-19 Brain and Skeletal Muscle Alterations. <i>Viruses</i> , <b>2021</b> , 13,	6.2	5
38	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , <b>2021</b> ,	2.4	2
37	Blockchain for increased trust in observational studies. <i>The Lancet Digital Health</i> , <b>2021</b> , 3, e762	14.4	

36	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. <i>E3S Web of Conferences</i> , <b>2021</b> , 319, 01035	0.5	
35	Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.. <i>Pharmaceutical Research</i> , <b>2022</b> , 39, 57	4.5	0
34	Neonatal COVID-19 exposures and infections: a systematic review of modes of transmission, manifestations and management. <i>Journal of Global Health Reports</i> ,	1.1	
33	Ganglioside binding domains in proteins: Physiological and pathological mechanisms.. <i>Advances in Protein Chemistry and Structural Biology</i> , <b>2022</b> , 128, 289-324	5.3	1
32	SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021.. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 796807	5.7	0
31	Long-Term Persistence of Olfactory and Gustatory Disorders in COVID-19 Patients.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 794550	4.9	1
30	Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.. <i>Pharmaceuticals</i> , <b>2022</b> , 15,	5.2	0
29	Hydroxychloroquine (HCQ) treatment for hospitalized patients with COVID- 19.. <i>Infectious Disorders - Drug Targets</i> , <b>2022</b> ,	1.1	
28	Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine. <i>Future Pharmacology</i> , <b>2022</b> , 2, 92-98		
27	Hydroxychloroquine/chloroquine and the risk of acute kidney injury in COVID-19 patients: a systematic review and meta-analysis.. <i>Renal Failure</i> , <b>2022</b> , 44, 415-425	2.9	0
26	Long-Term Study of Antibiotic Presence in Ebro River Basin (Spain): Identification of the Emission Sources. <i>Water (Switzerland)</i> , <b>2022</b> , 14, 1033	3	1
25	The ongoing Pharmacotherapy for ministration of Covid 19 disease: A Review. <i>Research Journal of Science and Technology</i> , <b>2022</b> , 66-72	1.5	
24	The prognostic role of micronutrient status and supplements in COVID-19 outcomes: A systematic review.. <i>Food and Chemical Toxicology</i> , <b>2022</b> , 112901	4.7	2
23	Coronavirus Disease 2019 and Hypertension: How Anti-Hypertensive Drugs Affect COVID-19 Medications and Vice Versa.. <i>Current Drug Safety</i> , <b>2022</b> ,	1.4	
22	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).. <i>Drugs - Real World Outcomes</i> , <b>2022</b> , 1	2.2	4
21	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. <i>International Journal of Infectious Diseases</i> , <b>2022</b> ,	10.5	0
20	Implementation of a fully remote randomized clinical trial with cardiac monitoring. <i>Communications Medicine</i> , <b>2021</b> , 1,		0
19	Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 23,	6.3	0

18	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <i>Anti-Infective Agents</i> , <b>2022</b> , 20,	0.6	
17	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 634	5.2	1
16	The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , <b>2022</b> ,	4.4	0
15	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , Volume 18, 603-617	2.9	0
14	Serum Free Zinc Is Associated With Vaccination Response to SARS-CoV-2. <i>Frontiers in Immunology</i> , 13,	8.4	0
13	A systemic review on liquid crystals, nanoformulations and its application for detection and treatment of SARS [CoV- 2 (COVID 19). <i>Journal of Molecular Liquids</i> , <b>2022</b> , 362, 119795	6	1
12	Environmental and ecotoxicological effects of drugs used for the treatment of COVID 19. 10,		0
11	Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.		
10	Association between the Use of Antibiotics and the Development of Acute Renal Injury in Patients Hospitalized for COVID-19 in a Hospital in the Peruvian Amazon. <b>2022</b> , 11, 4493		
9	Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—possible prevention strategy for COVID-19?.		0
8	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.		0
7	Snapshot of COVID-19 superinfections in Marseille hospitals: where are the common pathogens?. 1-16		1
6	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics).		1
5	Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study. <b>2023</b> , 16,		1
4	Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future. <b>2023</b> , 24, 1923		0
3	Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in Sã Paulo, Brazil: A non-randomized clinical trial preliminary study. <b>2023</b> , e15337		0
2	Challenges and Chances of Classical Cox Regression. <b>2022</b> , 2438-2449		0
1	Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients.		0

